| 货号 | 规格 | 价格 | 上海 | 北京 | 珠海 | 重庆 | 武汉 | 购买数量 |
|---|---|---|---|---|---|---|---|---|
V37849-1mg |
≥99% | ￥460.00 |
货期：3-5天 | - | - | - | - |
|
V37849-5mg |
≥99% | ￥1000.00 |
货期：3-5天 | - | - | - | - |
|
V37849-10mg |
≥99% | ￥1600.00 |
货期：3-5天 | - | - | - | - |
|
V37849-25mg |
≥99% | ￥3150.00 |
货期：3-5天 | - | - | - | - |
|
V37849-50mg |
≥99% | ￥4480.00 |
货期：3-5天 | - | - | - | - |
|
V37849-100mg |
≥99% | ￥7280.00 |
货期：3-5天 | - | - | - | - |
|
V37849-200mg |
≥99% | ￥9790.00 |
货期：3-5天 | - | - | - | - |
|
| 体内研究： | Balcinrenone (AZD9977) (oral administration; 10-100 mg/kg; 4 weeks) dose dependently reduces the UACR compared to vehicle in uni-nephrectomised male Sprague Dawley rats administered aldosterone and fed a high-salt diet. Balcinrenone is as efficacious as full MR antagonists on renal protection, despite the partial antagonism observed in in vitro assays. Balcinrenone (oral administration; 100 mg/kg; co-administration with enalapril) stops further disease progression and reduces the urine albumin excretion (UAE) compared to vehicle treatment. Co-administration of enalapril has an apparent additive effect on UAE reduction, although this reduction is not statistically significant. |
||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 参考文献： | 1. Fredrik Erlandsson, et al. Clinical safety, tolerability, pharmacokinetics and effects on urinary electrolyte excretion of AZD9977, a novel, selective mineralocorticoid receptor modulator. Br J Clin Pharmacol. 2018 Jul;84(7):1486-1493. | ||||||||||||||||||||
| 保存条件： | -20℃ | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
